Verastem pairs a four-quarter earnings beat streak and rapid revenue ramp with heavy cash burn, single-product concentration and meaningful short interest in a binary biotech setup.
Thesis pillars
- Earnings Beat Streak→Stable
- Rapid Revenue Ramp↑Improving
- Heavy Cash Burn→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 11, 2026, based on the 10-K filed Mar 4, 2026
Verastem, Inc. (VSTM) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $9.85: Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
Verastem is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, marketing AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib) as the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer following... Read more
Sell if holding. Multiple concerning factors at $9.85: Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
About Verastem, Inc.
About Verastem, Inc.
Verastem's AVMAPKI FAKZYNJA CO-PACK, the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer, received accelerated approval on May 8, 2025 and generated $30.9 million in net product revenue during its first seven months of commercial launch. The combination therapy is only commercially available in the United States, where an estimated 6,000 to 8,000 women live with LGSOC, and roughly 30% carry a KRAS mutation.
AVMAPKI FAKZYNJA CO-PACK reaches patients through designated specialty pharmacies and distributors, with the product available within five days of approval through two specialty pharmacies onboarded in the second quarter of 2025 and four specialty distributors added in the third quarter; the company estimates the top 100 commercial healthcare organizations in the U.S. represent approximately 50% of the sales opportunity for the drug. Verastem licensed its KRAS G12D inhibitor VS-7375 from GenFleet Therapeutics in January 2025, with GenFleet separately developing the same molecule as GFH375 in China under its own trials. A September 2021 clinical collaboration with Amgen to combine avutometinib with Amgen's LUMAKRAS was discontinued in December 2025 so the company could redirect resources toward VS-7375. Verastem competes against numerous large pharmaceutical and biotechnology companies pursuing RAS/MAPK pathway therapies, including AbbVie and AstraZeneca.
Show full overview
Verastem's business rests on a single approved product still under conditional authorization: the 10-K states the company is highly dependent on the commercial success of AVMAPKI FAKZYNJA CO-PACK for the foreseeable future, and because the drug holds accelerated rather than full approval, continued marketing depends on confirming clinical benefit in the ongoing Phase 3 RAMP 301 trial, with a topline progression-free-survival readout not expected until mid-2027. Enrollment finished a quarter ahead of schedule in October 2025, but a negative or inconclusive result at that 2027 readout could jeopardize the product's continued approval, not just future label expansion.
See also: Healthcare · Biotechnology
From Verastem, Inc.'s most recent 10-K filing, extracted July 19, 2026.
Recent developments
updated Nov 1, 2026Recent Developments — Verastem, Inc.
Latest news
- NEWS Verastem stock heads toward November 5 results after $250 million offering - ad-hoc-news.de — ad-hoc-news.de Nov 1, 2026 neutral
- NEWS VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes - Stockt — Stocktwits Oct 31, 2026 positive
- NEWS Verastem (VSTM) Stock Forum and Discussion - Moomoo — Moomoo Oct 29, 2026 neutral
- NEWS Verastem reports 50 percent response rate. Verastem stock is valued at USD 890.7 million - ad-hoc-news.de — ad-hoc-news.de Oct 29, 2026 positive
- NEWS BTIG raised target for Verastem Oncology stock from USD 18.00 to USD 24.00 - ad-hoc-news.de — ad-hoc-news.de Oct 27, 2026 positive
Latest item Nov 1, 2026 · Generated 2026-11-05T11:54:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAVMAPKI FAKZYNJA CO-PACK10-K Item 1A: 'We are highly dependent on the commercial success of AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S for the foreseeable future.'
- MEDIUMCustomertop 100 commercial healthcare organizations50%10-K Item 1: 'the top 100 commercial healthcare organizations in the U.S. comprise approximately 50% of the sales opportunity'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $9.85: Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $9.16. Score 5.4/10, moderate confidence.
Analyst target: $14.89 (+51.1% upside). Prior stop was $9.16. Stop-loss: $9.16.
Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7); Leverage penalty (D/E 1.7): -1.0.
Verastem, Inc. trades at a P/E of N/A (forward -8.1). TrendMatrix value score: 5.8/10. Verdict: Sell.
16 analysts rate VSTM, with a consensus score of 4.3/5. 9 analysts publish price targets averaging $17.
What does Verastem, Inc. do?Verastem is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, marketing AVMAPKI...
Verastem is a commercial-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, marketing AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib) as the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer following accelerated approval on May 8, 2025. The product generated $30.9 million in net product revenue during its first seven months of commercial launch in 2025, while the company advances VS-7375, a KRAS G12D inhibitor licensed from GenFleet Therapeutics in January 2025, through Phase 1/2 trials.